Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation for Antihypertensive Drug in Renal Cell Carcinoma

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Cancer type</td><td class="align_center">Concordance index score</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Renal cell clear cell carcinoma</td><td class="align_center">0.687</td></tr><tr><td class="align_left">Uveal melanoma</td><td class="align_center">0.590</td></tr><tr><td class="align_left">Prostate adenocarcinoma</td><td class="align_center">0.535</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

BioMed Research International

tab2

Table 2

Table 2: Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation for Antihypertensive Drug in Renal Cell Carcinoma 